Immunotherapy Toxicity
- 28 January 2019
- journal article
- research article
- Published by Elsevier BV in Hematology/Oncology Clinics of North America
- Vol. 33 (2), 275-290
- https://doi.org/10.1016/j.hoc.2018.12.008
Abstract
No abstract availableKeywords
Funding Information
- BMS
- Merck
- Novartis
- Lilly
- Checkmate
This publication has 50 references indexed in Scilit:
- Nivolumab versus Everolimus in Advanced Renal-Cell CarcinomaThe New England Journal of Medicine, 2015
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated MelanomaThe New England Journal of Medicine, 2015
- Pembrolizumab versus Ipilimumab in Advanced MelanomaThe New England Journal of Medicine, 2015
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patientsNature, 2014
- Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving NivolumabJournal of Clinical Oncology, 2014
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerThe New England Journal of Medicine, 2012
- Autoimmunity associated with immunotherapy of cancerBlood, 2011
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaThe New England Journal of Medicine, 2010
- Control of peripheral T‐cell tolerance and autoimmunity via the CTLA‐4 and PD‐1 pathwaysImmunological Reviews, 2008
- Selecting and maintaining a diverse T-cell repertoireNature, 1999